ClinicalTrials.gg
CompletedNCT01396239Updated Mar 30, 2020Results posted

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

A Phase 2 interventional study of AVI-4658 (Eteplirsen) and Placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 7 Years to 13 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
7 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
8th of 11
12 · median 15
Started
2011
the only one that year
Phase 2
7 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 3rd registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).

Read the detailed description

For details regarding the roll-over extension study 4658-us-202, please refer to NCT01540409.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
04

Who can participate

Ages eligible
7 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Major Inclusion and Exclusion Criteria:

Inclusion criteria

Inclusion Criteria:

A subject must meet all of the following criteria to be eligible for this study.

  • Be a male with DMD and have an out-of-frame deletion(s) that may be corrected by skipping exon 51 [e.g., deletions of exons 45-50, 47-50, 48-50, 49-50, 50, 52, 52-63], as confirmed in a Clinical Laboratory Improvement Act-accredited laboratory by any of the peer-reviewed and published methodology that evaluates all exons (including, but not limited to, multiplex ligation-dependent probe, comparative genomic hybridization, and single condition amplification/internal primer analysis).
  • Be between the ages of 7 and 13 years, inclusive.
  • Have stable cardiac function and stable pulmonary function (forced vital capacity [FVC] ≥50% of predicted and not require supplemental oxygen) that, in the Investigator's opinion, is unlikely to decompensate over the duration of the study.
  • Be receiving treatment with oral and have been on a stable dose for at least 24 weeks before study entry. Subjects may be allowed to take other (non-RNA antisense or gene therapy) medication (including angiotensin-converting enzyme [ACE] inhibitors, β blockers, losartan potassium, and coenzyme Q) as long as they have been on a stable dose of the medication for 24 weeks before the screening visit (Visit 1) and the dose will remain constant throughout the study.
  • Have intact right and left biceps muscles or an alternative upper arm muscle group.
  • Achieve an average distance within 200m and 400m ±10% (i.e. within 180m and 440m) while walking independently over six minutes.
  • Have a (LVEF) of >40% based on the ECHO that is obtained at the screening visit (Visit 1). A subject who has abnormal ECHO findings but who has an LVEF of >40% may be enrolled in the study at the Investigator's discretion; however, the subject must have been receiving stable doses of ACE inhibitors or β blockers for at least 24 weeks before study entry.
  • Have a parent(s) or legal guardian(s) who is able to understand and comply with the all of the study procedure requirements.
  • Be willing to provide informed assent and have a parent(s) or legal guardian(s) who is willing to provide written for the subject to participate in the study.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from this study.

  • Use of any pharmacologic treatment, other than , that might have an effect on muscle strength or function within 12 weeks before study entry (e.g., growth hormone, anabolic steroids).
  • Previous treatment with the experimental agents eteplirsen, BMN-195, or PRO051.
  • Previous treatment with any other experimental agents or participation in any other DMD interventional clinical study within 12 weeks before entry into this study; including use of the shock training system or "STS," or planned use during this study.
  • Surgery within 3 months before study entry or planned surgery at any time during this study.
  • Presence of other illness at the time of study entry, including significant renal dysfunction (as measured by urinary cystatin C, KIM-1, or urinary total protein), or average heart rate during screening Holter monitoring in excess of 110 bpm (unless subsequently treated and confirmed controlled and stable on a β-blocker) or >450 ms.
  • Use of any aminoglycoside antibiotic within 12 weeks before the screening visit (Visit 1) or need for use of an aminoglycoside antibiotic during the study (unless discussed and agreed with the Principal Investigator and medical monitor).
  • Prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the subject or that makes it unlikely that the course of treatment or follow-up would be completed or could impair the assessment of study results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    AVI-4658 (Eteplirsen)

    1. 50 mg/kg eteplirsen for 28 weeks 2. 30 mg/kg eteplirsen for 28 weeks

    Drug: AVI-4658 (Eteplirsen)

  • Placebo comparator
    Placebo / Delayed Treatment

    3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks. 3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks.

    Other: Placebo

Interventions

  • DrugEteplirsenStudies of EteplirsenEteplirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen

    Also known as: Eteplirsen- Phosphorodiamidate Morphilino Oligomer

  • OtherPlacebo

    sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.

    Also known as: Phosphate buffered saline

06

What researchers measure

Primary outcomes

  1. Change in the Number (%) of Dystrophin Positive Fibers

    The primary efficacy endpoint will be based on the pre-treatment and post-treatment change in the number (%) of dystrophin positive fibers as measured in the muscle biopsy tissue on immunohistochemistry (IHC).

    Time frame: After 12 weeks for 4 patients who received 50 mg/kg and 2 patients who received placebo. After 24 weeks for 4 patients who received 30 mg/kg and 2 patients who received placebo.

Secondary outcomes

  1. Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)

    A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment Change from baseline: 6 Minute Walk Test (6MWT) - Intent to Treat population (ITT)

    Time frame: 24 weeks

  2. Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)

    A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment of the 6-MWT distance. Change from baseline: 6 Minute Walk Test (6MWT) - modified Intent-to-Treat population (mITT).

    Time frame: 24 weeks

07

Results

Posted Nov 9, 2015
Limitations and caveats
Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the "Post-Hoc Outcome Measures" #4 and #5 for a summary of frequent and related AEs.

Participant flow

Participant flow — Overall Study
MilestoneAVI-4658 (Eteplirsen) 50 mg/kgPlacebo - Week 12 BiopsyAVI-4658 (Eteplirsen) 30 mg/kgPlacebo - Week 24 Biopsy
Started4242
Completed4242
Not completed0000

Outcome measures

PrimaryChange in the Number (%) of Dystrophin Positive Fibers

The primary efficacy endpoint will be based on the pre-treatment and post-treatment change in the number (%) of dystrophin positive fibers as measured in the muscle biopsy tissue on immunohistochemistry (IHC).

Time frame:
After 12 weeks for 4 patients who received 50 mg/kg and 2 patients who received placebo. After 24 weeks for 4 patients who received 30 mg/kg and 2 patients who received placebo.
Reported as:
Least squares mean · percentage of dystrophin Pos. fibers
Change in the Number (%) of Dystrophin Positive Fibers
percentage of dystrophin Pos. fibersAVI-4658 (Eteplirsen) 30 mg/kgPlacebo - Week 24 BiopsyAVI-4658 (Eteplirsen) 50 mg/kgPlacebo - Week 12 Biopsy
Change in the Number (%) of Dystrophin Positive Fibers23 (15.9 to 29.0)-7.48 (-8.5 to -6.5)0.79 (-9.3 to 7.4)-0.63 (-5.8 to 4.5)
SecondaryChange From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)

A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment Change from baseline: 6 Minute Walk Test (6MWT) - Intent to Treat population (ITT)

Time frame:
24 weeks
Reported as:
Mean · Meters
Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)
Meters30 mg/kg Eteplirsen50 mg/kg EteplirsenPlacebo
Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)-134.8 ± 72.36-2.3 ± 14.95-17.3 ± 14.03
SecondaryChange From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)

A key secondary efficacy endpoint will be based on the pre-treatment and post-treatment of the 6-MWT distance. Change from baseline: 6 Minute Walk Test (6MWT) - modified Intent-to-Treat population (mITT).

Time frame:
24 weeks
Reported as:
Mean · Meters
Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)
Meters30mg/kg Eteplirsen50mg/kg EteplirsenPlacebo
Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)-12.5 ± 1.50-2.3 ± 14.95-17.3 ± 14.03
Post-hocAdverse Events >30%

Adverse events that occurred in \>30% of the overall patient population across treatment arms.

Time frame:
24 Weeks
Reported as:
Number · Number of patients
Adverse Events >30%
Number of patientsAVI-4658 (Eteplirsen) - 30mg/kgAVI-4658 (Eteplirsen) - 50mg/kgPlacebo
Procedural Pain133
Oropharyngeal Pain303
Hypokalemia (a known side effect of steroids)222
Cough112
Extremity Pain013
Post-hocFrequency of AEs Related to Eteplirsen

Frequency of AEs that the study physician considered to be any of the following: Related; Possibly related; or Probably related to eteplirsen.

Time frame:
24 Weeks
Reported as:
Number · Number of patients
Frequency of AEs Related to Eteplirsen
Number of patientsAVI-4658 (Eteplirsen) - 30mg/kgAVI-4658 (Eteplirsen) - 50mg/kgPlacebo
Intermittent Nausea (mild)001
Other AEs related to eteplirsen000

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AVI-4658 (Eteplirsen) - 30mg/kg—0/4 (0%)4/4 (100%)
AVI-4658 (Eteplirsen) - 50mg/kg—0/4 (0%)4/4 (100%)
Placebo—0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAVI-4658 (Eteplirsen) - 30mg/kgAVI-4658 (Eteplirsen) - 50mg/kgPlacebo
Procedural painInjury, poisoning and procedural complications1/43/43/4
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/40/43/4
Pain in ExtremityMusculoskeletal and connective tissue disorders0/41/43/4
Back painMusculoskeletal and connective tissue disorders1/40/42/4
CoughRespiratory, thoracic and mediastinal disorders1/41/42/4
Nasal CongestionRespiratory, thoracic and mediastinal disorders1/40/42/4
Balance DisorderNervous system disorders1/42/40/4
HeadacheNervous system disorders1/40/42/4
PyrexiaGeneral disorders1/40/42/4
HypokalaemiaMetabolism and nutrition disorders2/42/42/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AVI-4658 (Eteplirsen) 30 mg/kgAVI-4658 (Eteplirsen) 50 mg/kgPlaceboTotal
<=18 years44412
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)AVI-4658 (Eteplirsen) 30 mg/kgAVI-4658 (Eteplirsen) 50 mg/kgPlaceboTotal
Mean9.3 ± 0.508.5 ± 1.298.5 ± 1.738.8 ± 1.22
Sex: Female, Male
Sex: Female, Male(Participants)AVI-4658 (Eteplirsen) 30 mg/kgAVI-4658 (Eteplirsen) 50 mg/kgPlaceboTotal
Female0000
Male44412
Region of Enrollment
Region of Enrollment(participants)AVI-4658 (Eteplirsen) 30 mg/kgAVI-4658 (Eteplirsen) 50 mg/kgPlaceboTotal
United States44412
08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Publications

  • Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E; Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb;79(2):257-71. doi: 10.1002/ana.24555. Epub 2016 Jan 8. PubMed 26573217 ↗
  • Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013 Nov;74(5):637-47. doi: 10.1002/ana.23982. Epub 2013 Sep 10. PubMed 23907995 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2011
First posted
Jul 18, 2011
Start
Jul 2011
Primary completionActual
Feb 2012
CompletionActual
Jun 2012
Results first posted
Nov 9, 2015
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01396239
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Jul 2011
Primary completion
Feb 2012
Completion
Jun 2012
Results posted
Nov 9, 2015
Last update
Mar 30, 2020

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion